HR and cancer: These findings underscored the versatility of Ad‐E6/7‐HR as a therapeutic agent to achieve improved clinical outcomes, holding promise for addressing limitations of monotherapy, such as immune evasion and drug resistance, in the treatment of HPV‐associated cancers.